ABSTRACT
OBJECTIVE: To estimate the prevalence of post-vaccination seropositivity against SARS-CoV-2 and identify its predictors in Peruvian Social Health Insurance (EsSalud) personnel in 2021. METHODS: We conducted a cross-sectional study in a representative simple stratified sample of EsSalud workers. We evaluated IgG anti-SARS-CoV-2 antibodies response (seropositivity) by passive (previous infection) and active immunization (vaccination), and epidemiological and occupational variables obtained by direct interview and a data collection form. Descriptive and inferential statistics were used with correction of sample weights adjusted for non-response rate, and crude and adjusted odds ratio (OR) and geometric mean ratio (GMR) with their respective 95% confidence intervals (95%CI) were estimated. RESULTS: We enrolled 1077 subjects. Seropositivity was 67.4% (95%CI: 63.4-71.1). Predictors of seropositivity were age (negative relation; p < 0.001), previous infection (aOR = 11.7; 95%CI: 7.81-17.5), working in COVID-19 area (aOR = 1.47; 95%CI: 1.02-2.11) and time since the second dose. In relation to antibody levels measured by geometric means, there was an association between male sex (aGMR = 0.77; 95%CI: 0.74-0.80), age (negative relation; p < 0.001), previous infection (aGMR = 13.1; 95%CI:4.99-34.40), non-face-to-face/licensed work modality (aGMR = 0.78; 95%CI: 0.73-0.84), being a nursing technician (aGMR = 1.30; 95%CI: 1.20-1.41), working in administrative areas (aGMR = 1.17; 95%CI: 1.10-1.25), diagnostic support (aGMR = 1.07; 95%CI: 1.01-1.15), critical care (aGMR = 0.85; 95%CI: 0.79-0.93), and in a COVID-19 area (aGMR = 1.30; 95%CI: 1.24-1.36) and time since receiving the second dose (negative relation; p < 0.001). CONCLUSIONS: Seropositivity and antibody levels decrease as the time since receiving the second dose increases. Older age and no history of previous infection were associated with lower seropositivity and antibody values. These findings may be useful for sentinel antibody surveillance and the design of booster dose strategies.
Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Male , COVID-19/epidemiology , COVID-19/prevention & control , Cross-Sectional Studies , Peru/epidemiology , Antibodies, ViralABSTRACT
La paquioniquia congnita (PC) es una rara genodermatosis de inicio en la infancia temprana caracterizada por una hiperqueratosis ungueal y frecuentes alteraciones asociadas. Se presenta el caso de una mujer de 28 a¤os con lesiones cl¡nicas compatibles con paquioniquia congnita tipo 1.
The pachyonychia congenita (PC) is a rare genodermatosis of onset in early infancy characterized by hyperkeratosis nail and frequent partner changes. The case of a 28 year old woman with clinical lesions compatible with pachyonychia congenita type 1 is presented.
Subject(s)
Humans , Adult , Female , Medical Illustration , Pachyonychia CongenitaABSTRACT
La poroqueratosis es un grupo de dermatosis raras que se producen debido a un trastorno del proceso de queratinizaci¢n. Hay diferentes formas cl¡nicas, pero caracter¡sticamente se presenta como p pulas delimitadas con centro ligeramente atr¢fico y borde elevado hiperquerat¢sico, pueden causar prurito. En la histopatolog¡a se puede observar las lamelas carnoides y la hipogranulosis como caracter¡sticas importantes. Se presenta el caso de un paciente var¢n de 32 a¤os de edad con lesiones en la regi¢n genital una localizaci¢n rara para esta enfermedad pero con cl¡nica e histopatolog¡a t¡picas, que fue tratado con crioterapia.
The porokeratosis is a rare dermatosis occurring due to a disorder of keratinization process. There are different clinical forms, but characteristically arises as papules delimited with center slightly atrophic and edge high hyperkeratotic, which can cause itching. The histopathology, you can see the lamellae carnoides and the hipogranulosis as important features. A case of a 32-year-old male patient is presented with lesions in the genital region, a rare location for this disease but with typical clinical and histopathology, which was treated with cryotherapy.
